EFFICACY AND SAFETY OF NATALIZUMAB TREATMENT FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS: INTERIM RESULTS OF THE TYSABRI(R) OBSERVATIONAL PROGRAMME IN THE UK.In this interim analysis of UK TOP results, patients treated with natalizumab had significantly improved ARRs, regardless of baseline treatment or relapse history. EDSS scores remained stable over time. Safety data were consistent with natalizumab's known safety profile. Analyses of UK TOP data over longer periods of time will further characterise the effect of natalizumab on disability, as well as on other long-term efficacy and safety parameters in a real-world setting.
Predictors of successful acceptance of home telemanagement in veterans with Multiple Sclerosis.
Time and time-frequency analysis of near-infrared signals for the assessment of ozone autohemotherapy long-term effects in multiple sclerosis.
Decoding movement intent of patient with multiple sclerosis for the powered lower extremity exoskeleton.
Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone.
Comprehensive analysis of human endogenous retrovirus group HERV-W locus transcription in multiple sclerosis brain lesions by high throughput amplicon sequencing.
Younger age, female sex, and high number of awakenings and arousals predict fatigue in patients with sleep disorders: a retrospective polysomnographic observational study.Younger age, female sex, and high number of awakenings and arousals are predictive of fatigue in sleep-disordered patients. Further investigations are needed to find the pathophysiological explanation for these relationships.
DEMYELINATION COMPLICATING ANTI-TNF THERAPY IN INFLAMMATORY BOWEL DISEASE (IBD) AND OTHER INFLAMMATORY DISORDERS (PRED4-UKCRN 11988).
AUDIT ON INTRAVENOUS IMMUNOGLOBULIN (IVIG) USE IN ABERDEEN ROYAL INFIRMARY NEUROLOGY DEPARTMENT ACCORDING TO 2005 ASSOCIATION OF BRITISH NEUROLOGISTS (ABN) GUIDELINES.
REGIONAL PATTERNS OF GREY MATTER ATROPHY AND MAGNETISATION TRANSFER RATIO ABNORMALITIES IN MULTIPLE SCLEROSIS CLINICAL SUBGROUPS.Assuming that reduced GM MTR implies demyelination and atrophy reflects neuronal loss, the results suggest that: (i) in progressive (SP and PP) MS there is overall more extensive GM demyelination than neuronal loss; (ii) in RRMS there is overall more extensive GM neuronal loss with less noticeable demyelination, (iii) cortical demyelination occurs in more regions in SPMS and PPMS than RRMS; (iv) demyelination and neuronal loss often occur in different locations in the cortex, and (v) co-existent demyelination and neuronal loss is most evident in the thalamus. The variation in regional abnormalities argue against a single common mechanism for demyelination and neuronal loss in MS GM.
NEUTRALISING ANTIBODIES TO INTERFERON-BETA PREDICT CONVERSION TO SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS IN PATIENTS WITH MULTIPLE SCLEROSIS.This study demonstrates a significantly increased risk of progression from RRMS to SPMS in patients who become NAb positive. As no current disease modifying treatments are effective in this phase of the disease patients at risk should be detected early and routine NAb testing can help to inform this decision.
A DECADE OF DATA FOR THE UK MULTIPLE SCLEROSIS RISK-SHARING SCHEME.
CLICK ON "Read More" FOR 70 MORE STUDIES & STORIES IN THIS WEEKS NEWS
CLICK ON "Read More" FOR 70 MORE STUDIES & STORIES IN THIS WEEKS NEWS
The interaction between smoking and Epstein-Barr virus as multiple sclerosis risk factors may depend on age.
Immunological and clinical consequences of splenectomy in a multiple sclerosis patient treated with natalizumab.Splenectomy may increase the risk for the development of natalizumab-associated PML via effects on the B cell compartment. It may be regarded as a risk factor in MS patients independent from the duration of disease.
Medscape Education for Neurologist: 2013 Insomnia Update: A Focus on Clinical Pathways and Why They Matter
Evidence-based patient information program in early multiple sclerosis: a randomised controlled trial
Elan Announces Webcast of Third Quarter 2013 Financial Results - 4:16pm EDT
Characterizing aggressive multiple sclerosis
A DECADE OF DATA FOR THE UK MULTIPLE SCLEROSIS RISK-SHARING
LATE-ONSET MULTIPLE SCLEROSIS
MOST NEUROLOGISTS IN SCOTLAND DO NOT USE THE MCDONALD 2010 CRITERIA TO DIAGNOSE MULTIPLE SCLEROSIS
Neuropsychological, balance and mobility risk factors for falls in people with multiple sclerosis: a prospective cohort study.
The study reveals important balance, coordination and cognitive determinants of falls in PwMS. These should assist the development of effective strategies for prevention of falls in this high-risk group
Postural control, falls and fear of falling in people with multiple sclerosis without mobility aids.
Decreased NAA in Gray Matter is Correlated with Decreased Availability of Acetate in White Matter in Postmortem Multiple Sclerosis Cortex.
Depressive syndromes in neurological disorders.
Maintenance percutaneous posterior nerve stimulation for refractory lower urinary tract symptoms in patients with multiple sclerosis.
Prolonged PTNS treatment leads to a persistent improvement of LUTS in MS patients.
Cell-Based Reparative Therapies for Multiple Sclerosis.
Astrocytic A20 ameliorates experimental autoimmune encephalomyelitis by inhibiting NF-κB- and STAT1-dependent chemokine production in astrocytes.
Pivotal role of augmented αB-crystallin in tumor development induced by deficient TSC1/2 complex.
False positive radiographical evidence of pump catheter migration into the spinal cord.
Environmental factors acting during development to influence MS risk: insights from animal studies.
Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation.
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.
TNF Receptor 2 protects oligodendrocyte progenitor cells against oxidative stress.
Targeting Interleukin-6 in Inflammatory Autoimmune Diseases and Cancers.
Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta.
The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders.
Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study
Evidence-based patient information programme in early multiple sclerosis: randomised controlled trial
Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial
Characterising aggressive multiple sclerosis
Disease modification in multiple sclerosis: an update
Early White Matter Changes in Childhood Multiple Sclerosis: A Diffusion Tensor Imaging Study
Compliance to GILENYA (fingolimod) and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
Fingolimod initiators were more compliant, less likely to discontinue treatment, and discontinued later than patients who initiated self-injected DMT.
[Is MRI monitoring useful in clinical practice in patients with relapsing-remitting multiple sclerosis? Yes.]
Visualization of inflammation and demyelination in 2D2 transgenic mice with rodent MRI.
25-hydroxyvitamin D3 Concentration in Serum and Cerebrospinal Fluid of Patients with Remitting-relapse Multiple Sclerosis.
Adipocytokine Profile, Cytokine Levels and Foxp3 Expression in Multiple Sclerosis: a Possible Link to Susceptibility and Clinical Course of Disease.
Progression, Symptoms and Psychosocial Concerns among Those Severely Affected by Multiple Sclerosis: A Mixed-Methods Cross-Sectional Study of Black Caribbean and White British People.
Tumefactive multiple sclerosis and fingolimod: Immunotherapies and unintended consequences.
The neuropathology of obesity: insights from human disease.
Alterations of brain eicosanoid synthetic pathway in multiple sclerosis and in animal models of demyelination: Role of cyclooxygenase-2.
Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases.